Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Perinatal Medicine

Official Journal of the World Association of Perinatal Medicine

Editor-in-Chief: Dudenhausen, MD, FRCOG, Joachim W.

Ed. by Bancalari, Eduardo / Chappelle, Joseph / Chervenak, Frank A. / D'Addario , Vincenzo / Genc, Mehmet R. / Greenough, Anne / Grunebaum, Amos / Konje, Justin C. / Kurjak M.D., Asim / Romero, Roberto / Zalud, MD PhD, Ivica


IMPACT FACTOR 2018: 1.361
5-year IMPACT FACTOR: 1.578

CiteScore 2018: 1.29

SCImago Journal Rank (SJR) 2018: 0.522
Source Normalized Impact per Paper (SNIP) 2018: 0.602

Online
ISSN
1619-3997
See all formats and pricing
More options …
Volume 45, Issue 1

Issues

The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality

Ki Hoon Ahn
  • Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, South Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Na-Young Bae
  • Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, South Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Soon-Cheol Hong
  • Corresponding author
  • Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea University College of Medicine, 126-1 Anam-dong 5-ga, Seongbuk-gu, Seoul 136-705, South Korea, Fax: +82-2-921-5357
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ji-Sung Lee / Eun Hee Lee / Hee-Jung Jee / Geum-Joon Cho
  • Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, South Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Min-Jeong Oh
  • Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, South Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hai-Joong Kim
  • Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, South Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-04-28 | DOI: https://doi.org/10.1515/jpm-2015-0317

Abstract

Background:

The safety of preventive progestogen therapy for preterm birth remains to be established. This meta-analysis aimed to evaluate the effects of preventive progestogen therapy on neonatal mortality.

Methods:

Randomized controlled trials (RCTs) on the preventive use of progestogen therapy, published between October 1971 and November 2015, were identified by searching MEDLINE/PubMed, EMBASE, Scopus, ClinicalTrials.gov, Cochrane Library databases, CINAHL, POPLINE, and LILACS using “progesterone” and “preterm birth” as key terms. We conducted separate analyses according to the type of progestogen administered and plurality of the pregnancy.

Results:

Twenty-two RCTs provided data on 11,188 neonates. Preventive progestogen treatment in women with a history of preterm birth or short cervical length was not associated with increased risk of neonatal death compared to placebo in all analyzed progestogen types and pregnancy conditions. The pooled relative risks (95% confidence interval) of neonatal mortality were 0.69 (0.31–1.54) for vaginal progestogen in singleton pregnancies, 0.6 (0.33–1.09) for intramuscular progestogen in singleton pregnancies, 0.96 (0.51–1.8) for vaginal progestogen in multiple pregnancies, and 0.96 (0.49–1.9) for intramuscular progestogen in multiple pregnancies.

Conclusions:

The results of this meta-analysis suggest that administration of preventive progestogen treatment to women at risk for preterm birth does not appear to negatively affect neonatal mortality in single or multiple pregnancies regardless of the route of administration.

Keywords: Neonatal death; preterm birth; progestogen

References

  • [1]

    WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14, 1976. Acta Obstet Gynecol Scand. 1977;56:247–53.Google Scholar

  • [2]

    Steer P. The epidemiology of preterm labour. Br J Obset Gynaecol. 2005;112(Suppl 1):1–3.Google Scholar

  • [3]

    Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151–61.Web of ScienceGoogle Scholar

  • [4]

    Arpino C, Compagnone E, Montanaro ML, Cacciatore D, De Luca A, Cerulli A, et al. Preterm birth and neurodevelopmental outcome: a review. Childs Nerv Syst. 2010;26:1139–49.Google Scholar

  • [5]

    Iams JD. Clinical practice. Prevention of preterm parturition. N Engl J Med. 2014;370:254–61.Google Scholar

  • [6]

    Iams JD. Identification of candidates for progesterone: why, who, how, and when? Obstet Gynecol. 2014;123:1317–26.Google Scholar

  • [7]

    Ruddock NK, Shi SQ, Jain S, Moore G, Hankins GD, Romero R, et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol. 2008;199:391.e1–7.Google Scholar

  • [8]

    Administration FaD. 17α-Alpha hydroxyprogesteronecaproate for prevention of pretermbirth: overview of FDA background document. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-01-FDA-Background.pdf2007.

  • [9]

    Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379–85.Google Scholar

  • [10]

    Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357:454–61.Google Scholar

  • [11]

    Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien JM, Cetingoz E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012;206:124.e1–19.Google Scholar

  • [12]

    O’Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:687–96.Google Scholar

  • [13]

    Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet. 2009;373:2034–40.Google Scholar

  • [14]

    Briery CM, Veillon EW, Klauser CK, Martin RW, Chauhan SP, Magann EF, et al. Progesterone does not prevent preterm births in women with twins. South Med J. 2009;102:900–4.Google Scholar

  • [15]

    Ibrahim M, Ramy A, Ramy M, Younis M. Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertil Soc J. 2010;15:39–41.Google Scholar

  • [16]

    Combs CA, Garite T, Maurel K, Das A, Porto M. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol. 2010;203:248.e1–9.Google Scholar

  • [17]

    Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18–31.Google Scholar

  • [18]

    Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011;38:272–80.Google Scholar

  • [19]

    Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJ, et al. 17alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. Obstet Gynecol. 2011;118:513–20.Google Scholar

  • [20]

    Combs CA, Garite T, Maurel K, Das A, Porto M. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol. 2011;204:221.e1–8.Google Scholar

  • [21]

    Tan PC, King AS, Vallikkannu N, Omar SZ. Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial. Arch Gynecol Obstet. 2012;285:585–90.Google Scholar

  • [22]

    Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol. 2012;207:390.e1–8.Google Scholar

  • [23]

    Serra V, Perales A, Meseguer J, Parrilla JJ, Lara C, Bellver J, et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. Br J Obset Gynaecol. 2013;120:50–7.Google Scholar

  • [24]

    Senat MV, Porcher R, Winer N, Vayssiere C, Deruelle P, Capelle M, et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2013;208:194.e1–8.Google Scholar

  • [25]

    Awwad J, Usta IM, Ghazeeri G, Yacoub N, Succar J, Hayek S, et al. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. Br J Obset Gynaecol. 2015;122:71–9.Google Scholar

  • [26]

    Winer N, Bretelle F, Senat MV, Bohec C, Deruelle P, Perrotin F, et al. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2015;212:485.e1–10.Google Scholar

  • [27]

    Brizot ML, Hernandez W, Liao AW, Bittar RE, Francisco RP, Krebs VL, et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2015;213:82.e1–9.Google Scholar

  • [28]

    El-Refaie W, Abdelhafez MS, Badawy A. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet. 2015;293:61–7.Google Scholar

  • [29]

    van Os MA, van der Ven AJ, Kleinrouweler CE, Schuit E, Kazemier BM, Verhoeven CJ, et al. Preventing preterm birth with progesterone in women with a short cervical length from a low-risk population: a multicenter double-blind placebo-controlled randomized trial. Am J Perinatol. 2015;32:993–1000.Google Scholar

  • [30]

    Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985;151:574–7.Google Scholar

  • [31]

    Wood S, Ross S, Tang S, Miller L, Sauve R, Brant R. Vaginal progesterone to prevent preterm birth in multiple pregnancy: a randomized controlled trial. J Perinat Med. 2012;40:593–9.Google Scholar

  • [32]

    Johnson JW, Lee PA, Zachary AS, Calhoun S, Migeon CJ. High-risk prematurity – progestin treatment and steroid studies. Obstet Gynecol. 1979;54:412–8.Google Scholar

  • [33]

    Cetingoz E, Cam C, Sakalli M, Karateke A, Celik C, Sancak A. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet. 2011;283:423–9.Google Scholar

  • [34]

    Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357:462–9.Google Scholar

  • [35]

    Aboulghar MM, Aboulghar MA, Amin YM, Al-Inany HG, Mansour RT, Serour GI. The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reprod Biomed Online. 2012;25:133–8.Google Scholar

  • [36]

    Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbriere R, et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol. 2012;206:206.e1–9.Google Scholar

  • [37]

    Choudhary M, Suneja A, Vaid NB, Guleria K, Faridi MM. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor. Int J Gynaecol Obstet. 2014;126:60–3.Google Scholar

  • [38]

    Martinez de Tejada B, Karolinski A, Ocampo MC, Laterra C, Hosli I, Fernandez D, et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. Br J Obset Gynaecol. 2015;122:80–91.Google Scholar

  • [39]

    Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet. 2009;104:40–3.Google Scholar

  • [40]

    Caritis SN, Simhan HN, Zhao Y, Rouse DJ, Peaceman AM, Sciscione A, et al. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. Am J Obstet Gynecol. 2012;207:396.e1–8.Google Scholar

  • [41]

    Usta IM, Usta J, Nassar AH. 17-hydroxy progesterone caproate for preterm labor prevention: final blood levels. Am J Obstet Gynecol. 2013;208:337.Google Scholar

  • [42]

    Chang J, Zhao Y, Zhao W, Venkataramanan R, Caritis SN. Quality assessment of compounded 17-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2014;210:47.e1–7.Google Scholar

  • [43]

    Manuck TA, Watkins WS, Moore B, Esplin MS, Varner MW, Jackson GM, et al. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. Am J Obstet Gynecol. 2014;210:321.e1–21.Google Scholar

  • [44]

    Posaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P. Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod. 2000;15(Suppl 1): 129–48.Google Scholar

  • [45]

    O’Brien JM. Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens. Ultrasound Obstet Gynecol. 2013;42: 247–53.Google Scholar

  • [46]

    Romero R, Stanczyk FZ. Progesterone is not the same as 17alpha-hydroxyprogesterone caproate: implications for obstetrical practice. Am J Obstet Gynecol. 2013;208:421–6.Google Scholar

About the article

Received: 2015-09-13

Accepted: 2016-03-16

Published Online: 2016-04-28

Published in Print: 2017-01-01


Funding Source: College of Medicine, Korea University

Award identifier / Grant number: K1421631

This study was supported by grant No. K1421631 from the Korea University College of Medicine, Seoul, South Korea. We have no conflict of interest for this study.


The authors stated that there are no conflicts of interest regarding the publication of this article.


Citation Information: Journal of Perinatal Medicine, Volume 45, Issue 1, Pages 11–20, ISSN (Online) 1619-3997, ISSN (Print) 0300-5577, DOI: https://doi.org/10.1515/jpm-2015-0317.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Suk-Joo Choi
Obstetrics & Gynecology Science, 2017, Volume 60, Number 5, Page 405
[2]
Jeff A Keelan and John P Newnham
F1000Research, 2017, Volume 6, Page 1139
[3]
Adi L. Tarca, Wendy Fitzgerald, Piya Chaemsaithong, Zhonghui Xu, Sonia S. Hassan, Jean-Charles Grivel, Nardhy Gomez-Lopez, Bogdan Panaitescu, Percy Pacora, Eli Maymon, Offer Erez, Leonid Margolis, and Roberto Romero
American Journal of Reproductive Immunology, 2017, Volume 78, Number 3, Page e12686

Comments (0)

Please log in or register to comment.
Log in